Form 8-K Lucid Diagnostics Inc. For: May 13

Go back to Form 8-K Lucid Diagnostics Inc. For: May 13

Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

May 14, 2024 8:01 AM EDT

Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)

The analyst comments "We reiterate our BUY rating on Lucid Diagnostics (LUCD) shares and maintain our price target at $3. Before the market open on... More